Foresite
SlowingFiled to raiseSan Francisco, CABiotechnology, HealthcareLast fund filed July 2022
1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Foresite Capital Fund VI | July 2022 | Indefinite | $551M | 112 |
| Foresite Capital VI-AFiled to raise in 2021, with no closing reported yet. | 2021 | $17M | $0 | 0 |
| Foresite Labs Fund IFiled to raise in 2021, with no closing reported yet. | 2021 | $150M | $0 | 0 |
| Foresite Capital Fund V | November 2019 | $743M | $743M | 402 |
| Foresite Capital Fund IVFiled to raise in 2017, with no closing reported yet. | 2017 | $650M | $0 | 0 |
| Foresite Capital V-DFiled to raise in 2016, with no closing reported yet. | 2016 | $52M | $0 | 0 |
| Foresite Capital V-BFiled to raise in 2015, with no closing reported yet. | 2015 | $24M | $0 | 0 |
| Foresite Capital V-CFiled to raise in 2015, with no closing reported yet. | 2015 | $5M | $0 | 0 |
| Foresite Capital Fund IIIFiled to raise in 2015, with no closing reported yet. | 2015 | $450M | $0 | 0 |
| Foresite Capital V-AFiled to raise in 2014, with no closing reported yet. | 2014 | $33M | $0 | 0 |
| Foresite Capital Fund II | December 2013 | $300M | $279M | 139 |
| Foresite Capital III-A | March 2012 | $11M | $11M | 33 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| James Tananbaum | Slowing | Biotech & pharma, Digital health, Medical devices | 14 | 1 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Foresite’s own portfolio companies, based on 8 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Foresite’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Bear Coast | 1 | Mindstrong |
| Caduceus Capital | 1 | Kinnate Biopharma |
| Dimension Capital | 1 | Eikon Therapeutics |
| General Catalyst | 1 | Mindstrong |
| Kleiner Perkins | 1 | Latigo Biotherapeutics |
| Longitude Capital | 1 | Allergen Research |
| Lux Capital | 1 | Eikon Therapeutics |
| Orbimed Genesis | 1 | Kinnate Biopharma |
| Samsara Biocapital | 1 | ALUMIS |
| Seaview Capital Partners | 1 | Kinnate Biopharma |
| Venbio Global Strategic | 1 | ALUMIS |
| Versant Venture Capital | 1 | Wavetec Vision Systems |
| Westlake Biopartners | 1 | Latigo Biotherapeutics |
A shared board seat: a company where filings name a Foresite partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.